A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density.
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2012
At a glance
- Drugs AMG 167 (Primary)
- Indications Metabolic bone diseases
- Focus Adverse reactions; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Jun 2011 Planned end date changed from 1 Mar 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.